PARP inhibitors (PARPi), including olaparib, act primarily by inhibiting DNA homologous repair mechanisms and were demonstrated to be effective in BRCA-deficient cancers, including ovarian carcinoma and breast cancer19,20. Here, PARP1 is linked to cancer.